Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Oman has been growing steadily in recent years.
Customer preferences: Customers in Oman are increasingly seeking treatment options for rheumatoid arthritis, osteoarthritis, and other autoimmune disorders. The preference for Anti-Rheumatic Drugs is driven by the effectiveness of these drugs in reducing inflammation and pain associated with these conditions. Patients in Oman are also becoming more aware of the benefits of early diagnosis and treatment, which has contributed to the growth of the Anti-Rheumatic Drugs market.
Trends in the market: The Anti-Rheumatic Drugs market in Oman is expected to grow in the coming years due to several factors. Firstly, the increasing prevalence of autoimmune disorders in the country is driving demand for these drugs. Secondly, the availability of a wide range of Anti-Rheumatic Drugs in the market has made it easier for patients to find a treatment option that suits their needs. Thirdly, the government's efforts to improve healthcare infrastructure and access to treatment have also contributed to the growth of the market.
Local special circumstances: One of the unique aspects of the Anti-Rheumatic Drugs market in Oman is the high prevalence of consanguineous marriages. This has led to a higher incidence of genetic disorders, including autoimmune disorders, which has contributed to the growth of the Anti-Rheumatic Drugs market. Additionally, Oman has a rapidly aging population, which is also driving demand for these drugs.
Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Oman is also influenced by broader macroeconomic factors. The country's strong economic growth and increasing per capita income have contributed to rising healthcare expenditure. Additionally, the government's focus on improving healthcare infrastructure and access to treatment has created a favorable environment for the growth of the Anti-Rheumatic Drugs market. However, the market is also subject to regulatory challenges, including the need for drug approvals and pricing regulations.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
